tert-butyl (1S,4R,6S)-6-[5-methyl-6-(2-methylpyridin-3-yl)oxypyrimidin-4-yl]oxy-2-azabicyclo[2.2.1]heptane-2-carboxylate | 1147559-00-9

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: tert-butyl (1S,4R,6S)-6-[5-methyl-6-(2-methylpyridin-3-yl)oxypyrimidin-4-yl]oxy-2-azabicyclo[2.2.1]heptane-2-carboxylate
• CAS: 1147559-00-9
• 化学式: C₂₂H₂₈N₄O₄
• 分子量: 412.489
• InChiKey: QOLHUCVLXVPCQL-RYRKJORJSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  30
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.55
• 拓扑面积：
  86.7
• 氢给体数：
  0
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  (1S)-(+)-2-氮杂双环[2.2.1]庚-5-烯-3-酮 在 lithium aluminium tetrahydride 、 potassium tert-butylate 、 mercury(II) diacetate 、 水 、 N,N-二异丙基乙胺 作用下， 生成 tert-butyl (1S,4R,6S)-6-[5-methyl-6-(2-methylpyridin-3-yl)oxypyrimidin-4-yl]oxy-2-azabicyclo[2.2.1]heptane-2-carboxylate
  参考文献：
  名称：

  Discovery of a nortropanol derivative as a potent and orally active GPR119 agonist for type 2 diabetes

  摘要：

  The lead optimization studies of a series of GPR119 agonists incorporating a nortropanol scaffold are described. Extensive structure-activity relationship (SAR) studies of the lead compound 20f led to the identification of compound 36j as a potent, single digit nanomolar GPR119 agonist with high agonist activity. Compound 36j was orally active in lowering blood glucose levels in a mouse oral glucose tolerance test and increased plasma insulin levels in a rat hyperglycemic model. It showed good to excellent pharmacokinetic properties in rats and monkeys and no untoward activities in counter-screen assays. Compound 36j demonstrated an attractive in vitro and in vivo profile for further development. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.04.035

文献信息

• BICYCLIC HETEROCYCLE DERIVATIVES AND THEIR USE AS MODULATORS OF THE ACTIVITY OF GPR119
  申请人：Xia Yan

  公开号：US20110212938A1

  公开（公告）日：2011-09-01

  The present invention relates to Bicyclic Heterocycle Derivatives, compositions comprising a Bicyclic Heterocycle Derivative, and methods of using the Bicyclic Heterocycle Derivatives for treating or preventing obesity, diabetes, a metabolic disorder, a cardiovascular disease or a disorder related to the activity of GPR119 in a patient.

  本发明涉及双环杂环衍生物、包含双环杂环衍生物的组合物以及使用双环杂环衍生物治疗或预防患者的肥胖症、糖尿病、代谢紊乱、心血管疾病或与GPR119活性相关的疾病的方法。
• US8907095B2
  申请人：——

  公开号：US8907095B2

  公开（公告）日：2014-12-09